E-Cigarette Liquids for Cardiopulmonary Health

Overseen By Paula Rodriguez Miguelez, PhD

Age: 18+

Sex: Any

Trial Phase: Phase < 1

Sponsor: Virginia Commonwealth University

Must not be taking: Cardiopulmonary medications

Disqualifiers: Cardiovascular, Pulmonary, Renal, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 2 weeks

64 Participants Needed

Trial Summary

What is the purpose of this trial?

Over the last decade, e-cigarettes have become increasingly popular, due to their promotion as a healthy alternative to traditional tobacco cigarettes. However, there are large discrepancies of knowledge in understanding how these e-cigarettes affect the user's health. The overall goal of this study is to evaluate the impact of e-cigarettes usage on user's cardiopulmonary health

Research Team

Paula Rodriguez Miguelez, PhD

Principal Investigator

Virginia Commonwealth University

Eligibility Criteria

This trial is for adults over the age of 21 who are either regular e-cigarette users (using them at least three times a week for more than three months) or those who have never used e-cigarettes. It's not specified, but typically people with certain health conditions may be excluded.

Inclusion Criteria

I am 21 or older and do not use e-cigarettes.

I am 21 or older and have been using e-cigarettes regularly for at least 3 months.

Exclusion Criteria

Use of cigarettes for 15 days or more in the past 60 days

I have heart, lung, kidney, liver, metabolic, or brain diseases.

Use of marijuana or any illicit or prescription drugs for non-medical use weekly or more frequently in the past 60 days

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants use assigned e-cigarette products or abstain from use for 2 weeks

2 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Tobacco flavored liquid type 1
• Tobacco flavored liquid type 2

Trial Overview The study is testing two types of tobacco-flavored liquids used in cartridge-based electronic cigarettes to see how they affect the heart and lungs of the users. Participants will use these liquids and their cardiopulmonary health will be monitored.

Participant Groups

Group I: E-cigarette liquid type 1 Experimental Treatment 1 Intervention

Participants will be instructed to use at least one study product daily in place of their own e-cigarettes during the intervention period.

Group II: E-cigarettes liquid type 2 Active Control 1 Intervention

Participants will be instructed to use at least one study product daily in place of their own e-cigarettes during the intervention period.

Group III: No e-cigarettes Active Control 1 Intervention

No e-cigarette use

Who Is Running the Clinical Trial?

Virginia Commonwealth University

Lead Sponsor

Trials

732

Recruited

22,900,000+